MARKET

SGMT

SGMT

Sagimet Biosciences Inc.
NASDAQ
5.81
+0.28
+5.07%
Opening 09:42 03/11 EDT
OPEN
5.77
PREV CLOSE
5.53
HIGH
6.00
LOW
5.77
VOLUME
56.82K
TURNOVER
--
52 WEEK HIGH
11.41
52 WEEK LOW
1.730
MARKET CAP
188.95M
P/E (TTM)
-3.2522
1D
5D
1M
3M
1Y
5Y
1D
Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress
TipRanks · 7h ago
Sagimet Biosciences Q4 net loss narrows as R&D expenses fall
Reuters · 7h ago
Sagimet Biosciences reports Q4 EPS (29c), consensus (43c)
TipRanks · 7h ago
Sagimet Biosciences Q4 EPS $(0.29) Beats $(0.48) Estimate
Benzinga · 7h ago
Sagimet Biosciences Q4 net loss narrows 41% to USD 9.57 million, cash falls 29% to USD 113.12 million
Reuters · 7h ago
SAGIMET BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES
Reuters · 7h ago
SAGIMET BIOSCIENCES Q4 EPS USD -0.29
Reuters · 7h ago
SAGIMET BIOSCIENCES Q4 NET INCOME USD -9.568 MILLION
Reuters · 7h ago
More
About SGMT
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

Webull offers Sagimet Biosciences Inc stock information, including NASDAQ: SGMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMT stock methods without spending real money on the virtual paper trading platform.